Journey Medical's revenue rebounded from $15.0M in 2025Q2 to $18.5M in 2026Q2, with year-over-year growth of 23.3%, and operating income turned marginally positive at $456.0K, suggesting early operating leverage.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.01+55.6% vs -$0.02 | $19M+0.8% vs $18M |
Q2 2026 May 13, 2026 | -$0.08-14.3% vs -$0.07 | $16M+3.2% vs $15M |
Q2 2026 Mar 25, 2026 | -$0.04+33.3% vs -$0.06 | $16M-14.7% vs $19M |
Q4 2025 Nov 12, 2025 | -$0.09-12.5% vs -$0.08 | $18M-6.5% vs $19M |
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET
Journey Medical (NASDAQ: DERM - Get Free Report) and Vireo Growth (OTCMKTS:VREOD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Risk and Volatility Journey Medical has a
Journey Medical (DERM) is rated Buy, driven by Emrosi's rapid prescription growth and expanding payer coverage. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and operating leverage, pushing toward sustainable profitability. Conservative growth assumptions and a 4x EV/Sales multiple yield a $15 target price, implying 109% upside over three years.
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.
Benchmark DERM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Journey Medical Corporation (DERM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.47 | $123.02M | -20.14 | 10.2% | -8.95% | -20.23% | — | |
| $15.71 | $102.23M | -5.60 | -10.02% | -6.33% | -32.11% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $146.51 | $10.15B | 23.74 | 30.73% | 13.45% | 29.48% | — | |
| $15.60 | $13.38M | -0.72 | 13.77% | -3881.54% | -70.23% | — |
Journey Medical Corporation (DERM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Journey Medical Corporation (DERM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 26, 2026·SEC
May 13, 2026·SEC
Get notified when DERM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Journey Medical Corporation (DERM) stock FAQ — growth, dividends, profitability & financials explained
Journey Medical Corporation (DERM) reported $68.2M in revenue over the trailing twelve months. Revenue was $61.9M in fiscal year 2025. That is 747% more than the $7.3M of fiscal year 2014.
Journey Medical Corporation (DERM) grew revenue by 20.9% over the trailing twelve months, compared with the twelve months before.
No. Journey Medical Corporation (DERM) reported a net loss of $6.1M over the trailing twelve months.
Journey Medical Corporation (DERM) had a return on equity (ROE) of -20.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Journey Medical Corporation (DERM) had negative free cash flow of $7.5M over the trailing twelve months.
